Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China.

IF 4.2 2区 医学 Q1 INFECTIOUS DISEASES Expert Review of Anti-infective Therapy Pub Date : 2024-06-01 Epub Date: 2024-02-01 DOI:10.1080/14787210.2024.2309998
Pulin Li, Ling Huang, Rui Han, Min Tang, Guanghe Fei, Daxiong Zeng, Ran Wang
{"title":"Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China.","authors":"Pulin Li, Ling Huang, Rui Han, Min Tang, Guanghe Fei, Daxiong Zeng, Ran Wang","doi":"10.1080/14787210.2024.2309998","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Since December 2022, the Omicron variant has led to a widespread pandemic in China. The study was to explore the safety and effectiveness of Paxlovid for the treatment of coronavirus disease 2019 (COVID-19).</p><p><strong>Research design and methods: </strong>We included patients at risk of developing severe COVID-19, all of whom exhibited mild to moderate symptoms and were admitted to three hospital centers. Patients were divided into two groups: one received Paxlovid alongside standard care, while the other was given only standard care. We compared clinical characteristics, hospital stay duration, and clinical outcomes between two groups. Multi-factor analysis determined the independent risk factors influencing the duration of hospitalization and disease progression.</p><p><strong>Results: </strong>In the study, those treated with Paxlovid shorter hospital stays than those in the control group (<i>p</i> < 0.001). Multivariate analysis indicated that the absence of Paxlovid treatment was a distinct risk factor for hospitalizations lasting over 7 days (OR: 4.983, 95% CI: 3.828-6.486, <i>p</i> < 0.001) and 14 days (OR: 2.940, 95% CI: 2.402-3.597, <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Amid the Omicron outbreak, Paxlovid has proven to be a safe and effective treatment for reducing hospitalization durations for patients with mild to moderate COVID-19.</p>","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"469-477"},"PeriodicalIF":4.2000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anti-infective Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14787210.2024.2309998","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Since December 2022, the Omicron variant has led to a widespread pandemic in China. The study was to explore the safety and effectiveness of Paxlovid for the treatment of coronavirus disease 2019 (COVID-19).

Research design and methods: We included patients at risk of developing severe COVID-19, all of whom exhibited mild to moderate symptoms and were admitted to three hospital centers. Patients were divided into two groups: one received Paxlovid alongside standard care, while the other was given only standard care. We compared clinical characteristics, hospital stay duration, and clinical outcomes between two groups. Multi-factor analysis determined the independent risk factors influencing the duration of hospitalization and disease progression.

Results: In the study, those treated with Paxlovid shorter hospital stays than those in the control group (p < 0.001). Multivariate analysis indicated that the absence of Paxlovid treatment was a distinct risk factor for hospitalizations lasting over 7 days (OR: 4.983, 95% CI: 3.828-6.486, p < 0.001) and 14 days (OR: 2.940, 95% CI: 2.402-3.597, p < 0.001).

Conclusion: Amid the Omicron outbreak, Paxlovid has proven to be a safe and effective treatment for reducing hospitalization durations for patients with mild to moderate COVID-19.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
奥米克龙流行期间,帕克洛维治疗轻中度COVID-19成人患者的安全性和有效性:一项来自中国的多中心研究。
背景:自2022年12月以来,奥米克变异株导致中国大范围流行。该研究旨在探讨帕克洛维治疗冠状病毒病2019(COVID-19)的安全性和有效性:我们纳入了有发生严重COVID-19风险的患者,他们均表现出轻度至中度症状,并在三家医院中心住院治疗。患者被分为两组:一组在接受标准治疗的同时接受 Paxlovid 治疗,另一组仅接受标准治疗。我们比较了两组患者的临床特征、住院时间和临床结果。多因素分析确定了影响住院时间和疾病进展的独立风险因素:在研究中,与对照组相比,接受 Paxlovid 治疗的患者的住院时间更短(p p p 结论:Paxlovid 治疗的患者的住院时间更短:在Omicron疫情中,Paxlovid被证明是一种安全有效的治疗方法,可缩短轻度至中度COVID-19患者的住院时间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.20
自引率
0.00%
发文量
66
审稿时长
4-8 weeks
期刊介绍: Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.
期刊最新文献
Could the next "disease X" be a pandemic of virus-induced encephalitis? What should our first medical response be? The opportunities and challenges of epigenetic approaches to manage herpes simplex infections. Potential activity of nanomaterials to combat SARS-CoV-2 and mucormycosis ‎coinfection‎. Clinical effectiveness of oral antivirals for non-hospitalized adult COVID-19 patients aged 18-60 years. Is self-medication with antibiotics among the public a global concern: a mixed-methods systematic review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1